AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $654.01 million. The enterprise value is $316.73 million.
| Market Cap | 654.01M |
| Enterprise Value | 316.73M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 27.32 million shares outstanding. The number of shares has decreased by -4.12% in one year.
| Shares Outstanding | 27.32M |
| Shares Change (YoY) | -4.12% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 1.90% |
| Owned by Institutions (%) | 111.38% |
| Float | 17.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.48 |
| Forward PS | 31.32 |
| PB Ratio | 13.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.53, with a Debt / Equity ratio of 0.36.
| Current Ratio | 11.53 |
| Quick Ratio | 11.20 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -161.40% and return on invested capital (ROIC) is -248.92%.
| Return on Equity (ROE) | -161.40% |
| Return on Assets (ROA) | -35.10% |
| Return on Capital (ROIC) | -248.92% |
| Revenue Per Employee | $196,256 |
| Profits Per Employee | -$1.40M |
| Employee Count | 117 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.34% in the last 52 weeks. The beta is -0.31, so AnaptysBio's price volatility has been lower than the market average.
| Beta (1Y) | -0.31 |
| 52-Week Price Change | +25.34% |
| 50-Day Moving Average | 22.91 |
| 200-Day Moving Average | 20.80 |
| Relative Strength Index (RSI) | 49.78 |
| Average Volume (30 Days) | 376,153 |
Short Selling Information
The latest short interest is 4.44 million, so 16.25% of the outstanding shares have been sold short.
| Short Interest | 4.44M |
| Short Previous Month | 4.37M |
| Short % of Shares Out | 16.25% |
| Short % of Float | 25.44% |
| Short Ratio (days to cover) | 11.43 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $22.96 million and -$163.30 million in losses. Loss per share was -$6.14.
| Revenue | 22.96M |
| Gross Profit | 22.96M |
| Operating Income | -162.21M |
| Pretax Income | -163.30M |
| Net Income | -163.30M |
| EBITDA | -160.92M |
| EBIT | -163.30M |
| Loss Per Share | -$6.14 |
Balance Sheet
The company has $354.67 million in cash and $17.39 million in debt, giving a net cash position of $337.28 million or $12.35 per share.
| Cash & Cash Equivalents | 354.67M |
| Total Debt | 17.39M |
| Net Cash | 337.28M |
| Net Cash Per Share | $12.35 |
| Equity / Book Value | 47.78M |
| Book Value Per Share | 1.75 |
| Working Capital | 340.12M |
Cash Flow
In the last 12 months, operating cash flow was -$133.49 million and capital expenditures -$659,000, giving a free cash flow of -$134.14 million.
| Operating Cash Flow | -133.49M |
| Capital Expenditures | -659,000 |
| Free Cash Flow | -134.14M |
| FCF Per Share | -$5.01 |
Margins
Gross margin is 100.00%, with operating and profit margins of -706.43% and -711.17%.
| Gross Margin | 100.00% |
| Operating Margin | -706.43% |
| Pretax Margin | -711.19% |
| Profit Margin | -711.17% |
| EBITDA Margin | -700.79% |
| EBIT Margin | -711.19% |
| FCF Margin | -584.20% |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.12% |
| Shareholder Yield | 4.12% |
| Earnings Yield | -24.97% |
| FCF Yield | -20.51% |
Analyst Forecast
The average price target for AnaptysBio is $46.38, which is 93.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $46.38 |
| Price Target Difference | 93.73% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 40.89% |
| EPS Growth Forecast (5Y) | 1.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of -1.44 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.44 |
| Piotroski F-Score | 4 |